

announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry.

**Kalwant Smagh,**

*Director, Office of Strategic Business Initiatives, Office of the Chief Operating Officer, Centers for Disease Control and Prevention.*

[FR Doc. 2023–23459 Filed 10–23–23; 8:45 am]

**BILLING CODE 4163–18–P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Centers for Disease Control and Prevention

#### Notice of Closed Meeting

Pursuant to 5 U.S.C section 1009(d), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), title 5 U.S.C., as amended, and the Determination of the Director, Office of Strategic Business Initiatives, Office of the Chief Operating Officer, CDC, pursuant to Public Law 92–463. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP)—CE24–034, Rigorous Evaluation of Policies for their Impacts on the Primary Prevention of Multiple Forms of Violence.

*Date:* February 27, 2024.

*Time:* 8 a.m.–5 p.m., EST.

*Place:* Web Conference.

*Agenda:* To review and evaluate grant applications.

*For Further Information Contact:* Carlisha Gentles, PharmD, BCPS, CDCES, Scientific Review Officer, National Center for Injury Prevention and Control, CDC, 4770 Buford Highway NE, Mailstop F–63, Atlanta, Georgia 30341, Telephone: (770)488–1504; Email: CGentles@cdc.gov.

The Director, Office of Strategic Business Initiatives, Office of the Chief Operating Officer, Centers for Disease Control and Prevention, has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other

committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry.

**Kalwant Smagh,**

*Director, Office of Strategic Business Initiatives, Office of the Chief Operating Officer, Centers for Disease Control and Prevention.*

[FR Doc. 2023–23458 Filed 10–23–23; 8:45 am]

**BILLING CODE 4163–18–P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Centers for Disease Control and Prevention

#### Board of Scientific Counselors, Deputy Director for Infectious Diseases

**AGENCY:** Centers for Disease Control and Prevention (CDC), Department of Health and Human Services (HHS).

**ACTION:** Notice of meeting.

**SUMMARY:** In accordance with regulatory provisions, the Centers for Disease Control and Prevention (CDC) announces the following meeting of the Board of Scientific Counselors, Deputy Director for Infectious Diseases (BSC, DDID). This virtual meeting is open to the public via Zoom, limited only by the number of web conference lines available (500 lines). Registration in advance is required by accessing the link below in the addresses section. Time will be available for public comment.

**DATES:** The meeting will be held on November 30, 2023, from 1:30 p.m. to 3 p.m., EST.

**ADDRESSES:** Zoom virtual meeting. Registration in advance is required by accessing the link at [https://cdc.zoomgov.com/webinar/register/WN\\_r2EU3xBTB6MBiQq\\_HdqNQ](https://cdc.zoomgov.com/webinar/register/WN_r2EU3xBTB6MBiQq_HdqNQ). Instructions to access the meeting will be provided following registration.

**FOR FURTHER INFORMATION CONTACT:** Sarah Wiley, MPH, Senior Advisor, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, 1600 Clifton Road NE, Mailstop H16–5, Atlanta, Georgia 30329–4037. Telephone: (404) 639–4840; Email: SWiley@cdc.gov.

**SUPPLEMENTARY INFORMATION:** *Purpose:* The Board of Scientific Counselors, Deputy Director for Infectious Diseases (BSC, DDID) provides advice and guidance to the Secretary, Department of Health and Human Services; the Director, Centers for Disease Control and Prevention (CDC); and the Directors

of the National Center for Emerging and Zoonotic Infectious Diseases, the National Center for HIV, Viral Hepatitis, STD, and TB Prevention, the National Center for Immunization and Respiratory Diseases, concerning strategies, goals, and priorities for the programs and research within the national centers and monitors the overall strategic direction and focus of CDC's infectious disease programs and centers.

*Matters To Be Considered:* The agenda will include updates and discussions on recent outbreaks and disease surveillance strategies, as well as a brief report from one of the Board's workgroups: the Food Safety Modernization Act Surveillance Working Group. Agenda items are subject to change as priorities dictate.

The Director, Office of Strategic Business Initiatives, Office of the Chief Operating Officer, Centers for Disease Control and Prevention, has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry.

**Kalwant Smagh,**

*Director, Office of Strategic Business Initiatives, Office of the Chief Operating Officer, Centers for Disease Control and Prevention.*

[FR Doc. 2023–23460 Filed 10–23–23; 8:45 am]

**BILLING CODE 4163–18–P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Centers for Disease Control and Prevention

#### Notice of Closed Meeting

Pursuant to section 5 U.S.C. Section 1009(d), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended, and the Determination of the Director, Office of Strategic Business Initiatives, Office of the Chief Operating Officer, CDC, pursuant to Public Law 92–463. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee: Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP)—CE24-011, Grants to Support New Investigators in Conducting Research Related to Understanding Drug Use and Overdose Risk and Protective Factors (K01).*

*Date:* March 5, 2024.

*Time:* 8:30 a.m.–5 p.m., EST.

*Place:* Web Conference.

*Agenda:* To review and evaluate grant applications.

*For Further Information Contact:* Aisha L. Wilkes, M.P.H., Scientific Review Officer, National Center for Injury Prevention and Control, Centers for Disease Control and Prevention, 4770 Buford Highway NE, Mailstop S106–9, Atlanta, Georgia 30341, Telephone: (404) 639–6473; Email: [AWilkes@cdc.gov](mailto:AWilkes@cdc.gov).

The Director, Office of Strategic Business Initiatives, Office of the Chief Operating Officer, Centers for Disease Control and Prevention, has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry.

**Kalwant Smagh,**

*Director, Office of Strategic Business Initiatives, Office of the Chief Operating Officer, Centers for Disease Control and Prevention.*

[FR Doc. 2023–23457 Filed 10–23–23; 8:45 am]

**BILLING CODE 4163–18–P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Administration for Children and Families

#### Title IV–E Prevention Services Clearinghouse Handbook of Standards and Procedures, Draft Version 2.0

**AGENCY:** Administration for Children and Families, Department of Health and Human Services.

**ACTION:** Request for public comment.

**SUMMARY:** The Administration for Children and Families (ACF), within the U.S. Department of Health and Human Services (HHS), oversees the Title IV–E Prevention Services Clearinghouse. ACF seeks comments on proposed changes and clarifications to existing standards and procedures in the *Handbook of Standards and Procedures, Version 2.0*.

**DATES:** The deadline for comments on this notice is November 24, 2023.

**ADDRESSES:** Interested parties may submit written questions, comments, and supplementary documents by email to [preventionservices@abtassoc.com](mailto:preventionservices@abtassoc.com) with “Title IV–E Prevention Services Clearinghouse FRN comment” in the subject line. To ensure that your comments have maximum effect, please identify clearly the section of the draft *Handbook of Standards and Procedures, Version 2.0* that your comments address.

Readers are referred to the full version of the draft *Handbook of Standards and Procedures, Version 2.0* on the Clearinghouse website (<https://preventionservices.acf.hhs.gov/resources/comment-draft-handbook>).

#### SUPPLEMENTARY INFORMATION:

##### 1.0 Background and Legislative Context

The Family First Prevention Services Act (FFPSA) was signed into law as part of the Bipartisan Budget Act (H.R. 1892) on February 9, 2018. FFPSA amended the Social Security Act (the Act) to enable use of Federal funds available under parts B and E of title IV of the Social Security Act to provide enhanced support to children and families and prevent foster care placements through the provision of evidence-based “mental health and substance abuse prevention and treatment services, in-home parent skill-based programs, and kinship navigator services.” As described in the statutory language, these services and programs are intended “for children who are candidates for foster care or who are pregnant or parenting foster youth and the parents or kin caregivers of the children.” The Act requires an independent systematic review of evidence to designate programs and services as “promising,” “supported,” and “well-supported” practices.

In order to meet these requirements, ACF established the Title IV–E Prevention Services Clearinghouse (the Clearinghouse). The Clearinghouse carries out a systematic review process implemented by trained reviewers using consistent, transparent standards and procedures. The *Handbook of Standards and Procedures, Version 1.0* (<https://preventionservices.acf.hhs.gov/review-process>) provides a detailed description of the standards used to identify and review programs and services for the Clearinghouse and the procedures followed by the Clearinghouse staff. The *Handbook of Standards and Procedures, Version 1.0* was informed by public comments submitted in response to **Federal Register** Notice 83 FR 29122 (<https://www.federalregister.gov/documents/2018/06/22/2018-13420/decisions-related-to-the-development-of->

*a-clearinghouse-of-evidence-based-practices-in-accordance*), consultations with research and practice experts, and the review processes developed and used by other prominent evidence clearinghouses.

#### 2.0 Overview of 2021 Request for Public Comment on Title IV–E Prevention Services Clearinghouse Handbook of Standards and Procedures, Version 1.0

ACF solicited feedback on the Prevention Services Clearinghouse *Handbook of Standards and Procedures, Version 1.0* (subsequently referred to as *Handbook Version 1.0*) through a **Federal Register** Notice 86 FR 37332 (<https://www.federalregister.gov/documents/2021/07/15/2021-15065/title-iv-e-prevention-services-clearinghouse-handbook-of-standards-and-procedures>) published on July 15, 2021. This comment period was open for 30 days and closed on August 16, 2021. One hundred four unique commenters submitted feedback, including 10 commenters from state and local child welfare agencies. Commenters included state and local government administrators, program and service developers, Federal staff, researchers and evaluators, foundation and non-profit organization staff, and other interested parties. ACF ensured the careful review and consideration of all of the comments in developing the draft *Handbook of Standards and Procedures, Version 2.0* (subsequently referred to as *Handbook Version 2.0*). Comments were considered within the context of the statutory requirements of FFPSA, the necessity to conduct a systematic, objective, and transparent evidence review, and resource considerations. The public comments informed discussions with a large number of experts whose comments were also considered in developing the proposed revisions.

*Summary of Comments.* Comments highlighted how the standards and procedures specified in *Handbook Version 1.0* might be revised to better reflect the goals and requirements of the *Executive Order on Advancing Racial Equity and Support for Underserved Communities Through the Federal Government*. For example, commenters recommended prioritizing the review of programs and services that have been implemented and/or studied with diverse populations (Section 2.2). Commenters also recommended engaging diverse individuals and those with lived experience to inform the systematic review process and allowing greater flexibility for culturally adapted programs and services. Commenters